BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18779591)

  • 1. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
    Bogorad RL; Courtillot C; Mestayer C; Bernichtein S; Harutyunyan L; Jomain JB; Bachelot A; Kuttenn F; Kelly PA; Goffin V; Touraine P;
    Proc Natl Acad Sci U S A; 2008 Sep; 105(38):14533-8. PubMed ID: 18779591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas.
    Courtillot C; Chakhtoura Z; Bogorad R; Genestie C; Bernichtein S; Badachi Y; Janaud G; Akakpo JP; Bachelot A; Kuttenn F; Goffin V; Touraine P;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):271-9. PubMed ID: 19897676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
    Kavarthapu R; Tsai Morris CH; Dufau ML
    Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of gain-of-function variants of the human prolactin receptor.
    Goffin V; Bogorad RL; Touraine P
    Methods Enzymol; 2010; 484():329-55. PubMed ID: 21036240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
    Kavarthapu R; Dufau ML
    Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
    Kavarthapu R; Dufau ML
    Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
    Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
    Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of prolactin receptor in GH signaling in breast cancer cells.
    Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
    Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk.
    Chakhtoura Z; Laki F; Bernadet M; Cherifi I; Chiche A; Pigat N; Bernichtein S; Courtillot C; Boutillon F; Bièche I; Vacher S; Tanguy ML; Bissery A; Grouthier V; Camparo P; Foretz M; Do Cruzeiro M; Pierre R; Rakotozafy F; Tichet J; Tejedor I; Guidotti JE; Sigal-Zafrani B; Goffin V; Touraine P
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4449-4460. PubMed ID: 27575941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
    Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
    Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
    Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
    Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.
    Lee SA; Haiman CA; Burtt NP; Pooler LC; Cheng I; Kolonel LN; Pike MC; Altshuler D; Hirschhorn JN; Henderson BE; Stram DO
    BMC Med Genet; 2007 Dec; 8():72. PubMed ID: 18053149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residue 146 regulates prolactin receptor folding, basal activity and ligand-responsiveness: potential implications in breast tumorigenesis.
    Zhang C; Cherifi I; Nygaard M; Haxholm GW; Bogorad RL; Bernadet M; England P; Broutin I; Kragelund BB; Guidotti JE; Goffin V
    Mol Cell Endocrinol; 2015 Feb; 401():173-88. PubMed ID: 25524456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha
    Castillo LF; Rivero EM; Goffin V; Lüthy IA
    Cell Signal; 2017 Jun; 34():76-85. PubMed ID: 28302567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways.
    Um M; Lodish HF
    J Biol Chem; 2006 Mar; 281(9):5648-56. PubMed ID: 16407271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R).
    Zhang Y; Gc S; Patel SB; Liu Y; Paterson AJ; Kappes JC; Jiang J; Frank SJ
    Mol Cell Endocrinol; 2019 Jul; 492():110445. PubMed ID: 31100495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
    Lim JH; Kim TY; Kim WH; Park JW
    Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin receptor regulates Stat5 tyrosine phosphorylation and nuclear translocation by two separate pathways.
    Ali S; Ali S
    J Biol Chem; 1998 Mar; 273(13):7709-16. PubMed ID: 9516478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connections between prolactin and ovarian cancer.
    Alkharusi A; AlMuslahi A; AlBalushi N; AlAjmi R; AlRawahi S; AlFarqani A; Norstedt G; Zadjali F
    PLoS One; 2021; 16(8):e0255701. PubMed ID: 34358244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.
    Fiorillo AA; Medler TR; Feeney YB; Wetz SM; Tommerdahl KL; Clevenger CV
    Am J Pathol; 2013 Jan; 182(1):217-33. PubMed ID: 23159947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.